Scholarlink

Purpose <p>We aim to evaluate the association between the use of glucosamine, a widely used dietary supplement, and the risk of IBD-related surgery in a prospective cohort study.</p> Methods <p>We leveraged data from 6059 individuals with IBD from the UK Biobank. Habitual use, frequency of use, and the dose of glucosamine were evaluated using self-reported records, multiple rounds of dietary recall, and prescription information from primary care data, respectively. IBD-related surgery was identified through inpatient data. Cox proportional-hazard model and logistic regression model were applied to examine the associations.</p> Results <p>During a mean follow-up of 12.2&#xa0;years, we documented 684 incident IBD-related surgery events. Compared with non-users, habitual glucosamine users presented (66.6 vs 97.1 cases/10,000 person-years, HR 0.73, 95% CI 0.58–0.92, <i>P</i> = 0.009) lowered risk of IBD-related surgery, decreased risk in Crohn’s disease (80.6 vs 131.0 cases/10,000 person-years, HR 0.60, 95% CI 0.41–0.89, <i>P</i> = 0.011), while it was not significant in ulcerative colitis (61.1 vs 79.5 cases/10,000 person-years, HR 0.88, 95% CI 0.65–1.18, <i>P</i> = 0.386). The risks of IBD-related surgery were also lower among occasional users (HR 0.34, 95% CI 0.15–0.77, <i>P</i> = 0.010) and constant users (HR 0.48, 95% CI 0.25–0.90, <i>P</i> = 0.022) than non-users. For those using prescribed glucosamine, a higher prescription dose was associated with a lower risk of related surgery (OR 0.15, 95% CI 0.02–0.86, <i>P</i> = 0.034).</p> Conclusion <p>Use of glucosamine, as a safe dietary supplement, is associated with a lower risk of IBD-related surgery, which would be a promising strategy in IBD management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dietary glucosamine supplement use and lower surgery risk in individuals with inflammatory bowel disease: a prospective Cohort Study

  • 期刊论文

  • 发表日期：

    2025年5月28日

查看全文
  • Jiawei Geng,
  • Xuejie Chen,
  • Sidan Wang,
  • Lintao Dan,
  • Qijia Gong,
  • Jie Chen,
  • Xiaoyan Wang,
  • Xiaocang Cao,
  • Zhongyan Du

摘要

Purpose

We aim to evaluate the association between the use of glucosamine, a widely used dietary supplement, and the risk of IBD-related surgery in a prospective cohort study.

Methods

We leveraged data from 6059 individuals with IBD from the UK Biobank. Habitual use, frequency of use, and the dose of glucosamine were evaluated using self-reported records, multiple rounds of dietary recall, and prescription information from primary care data, respectively. IBD-related surgery was identified through inpatient data. Cox proportional-hazard model and logistic regression model were applied to examine the associations.

Results

During a mean follow-up of 12.2 years, we documented 684 incident IBD-related surgery events. Compared with non-users, habitual glucosamine users presented (66.6 vs 97.1 cases/10,000 person-years, HR 0.73, 95% CI 0.58–0.92, P = 0.009) lowered risk of IBD-related surgery, decreased risk in Crohn’s disease (80.6 vs 131.0 cases/10,000 person-years, HR 0.60, 95% CI 0.41–0.89, P = 0.011), while it was not significant in ulcerative colitis (61.1 vs 79.5 cases/10,000 person-years, HR 0.88, 95% CI 0.65–1.18, P = 0.386). The risks of IBD-related surgery were also lower among occasional users (HR 0.34, 95% CI 0.15–0.77, P = 0.010) and constant users (HR 0.48, 95% CI 0.25–0.90, P = 0.022) than non-users. For those using prescribed glucosamine, a higher prescription dose was associated with a lower risk of related surgery (OR 0.15, 95% CI 0.02–0.86, P = 0.034).

Conclusion

Use of glucosamine, as a safe dietary supplement, is associated with a lower risk of IBD-related surgery, which would be a promising strategy in IBD management.